Pimitespib Explained

Tradename:	Jeselhy
Legal Status:	Rx in Japan
Synonyms:	TAS 116
Cas Number:	1260533-36-5
Unii:	PLO044MUDZ
Kegg:	D11920
C:	25
H:	26
N:	8
O:	1
Smiles:	O=C(N)C1=CC=C(C(=C1)CC)N2N=C(C=3C2=NC=CC3N4C=NC(=C4)C=5C=NN(C5)C)C(C)C

Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors.^[1] It was discovered and developed by Taiho Pharmaceutical Co.^[2] The mechanism of action of pimitespib involves inhibition of heat shock protein 90 (Hsp90).^[3]

In June 2022, it received approval in Japan for gastrointestinal stromal tumors that have progressed after chemotherapy.^[4]

Notes and References

1. Web site: Pimitespib - Taiho Pharmaceutical . Adis Insight .
2. Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST) . June 20, 2022 . Taiho Pharmaceutical .
3. Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T . 6 . Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial . Annals of Oncology . June 2022 . 33 . 9 . 959–967 . 35688358 . 10.1016/j.annonc.2022.05.518 . 249532381 . free .
4. Hoy SM . Pimitespib: First Approval . Drugs . August 2022 . 82 . 13 . 1413–1418 . 35986838 . 10.1007/s40265-022-01764-6 . 251672805 .